Combination of Novartis drugs Tafinlar and Mekinist shows significant survival benefit in patients with metastatic melanoma

Novartis has announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the...